11373
document
Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together . To explore the steady-state pharmacokinetic profile after coadministration of galantamine and risperidone , an open-label , randomized , single-center , two-way crossover drug-drug interaction study was conducted in 16 healthy elderly subjects , ages 60 years and older . The results showed that risperidone , when administered with galantamine , did not change the bioavailability of galantamine at steady state . In addition , systemic exposure of risperidone active moiety ( risperidone plus 9-hydroxyrisperidone ) , the most clinically relevant component of risperidone treatment , was not affected by galantamine coadministration , while systemic exposure was increased by approximately 10 % for risperidone and decreased by about 10 % for 9-hydroxyrisperidone ( active metabolite of risperidone ) . Galantamine and risperidone were both safe and well tolerated administered either alone or together . Thus , no dose adjustment for either risperidone orgalantamine is necessary when these two drugs are administered together in the dose range evaluated .
11374
Intervention_Pharmacological
galantamine
11375
Intervention_Pharmacological
risperidone
11376
Intervention_Pharmacological
galantamine
11377
Intervention_Pharmacological
risperidone
11378
Intervention_Pharmacological
risperidone
11379
Intervention_Pharmacological
galantamine
11380
Intervention_Pharmacological
galantamine
11381
Intervention_Pharmacological
risperidone
11382
Intervention_Pharmacological
risperidone plus 9-hydroxyrisperidone
11383
Intervention_Pharmacological
risperidone
11384
Intervention_Pharmacological
galantamine
11385
Intervention_Pharmacological
risperidone
11386
Intervention_Pharmacological
9-hydroxyrisperidone
11387
Intervention_Pharmacological
risperidone
11388
Intervention_Pharmacological
Galantamine
11389
Intervention_Pharmacological
risperidone orgalantamine
11390
Outcome_Other
Pharmacokinetic
11391
Outcome_Physical
and
11392
Outcome_Other
safety
11393
Outcome_Physical
assessments
11394
Outcome_Other
bioavailability
11395
Outcome_Other
systemic exposure
11396
Outcome_Other
safe and well tolerated